To Compare the Efficacy of Kalmegh Vati versus Amlodipine in Stage 1 Hypertensio
Phase 3
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2023/12/060794
- Lead Sponsor
- Dr Vinay Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients, willing to participate with written informed consent.
2.Age between 30-60 years of either sex.
Subjects having Systolic blood pressure 140-159mmHg & Diastolic blood pressure between 90-
99mmHg (Stage-1 hypertension as per JNC 8 guidelines).
Exclusion Criteria
1.Cases of major illness like cardiovascular disorders like cardiogenic shock, unstable angina,
aortic stenosis, diabetes mellitus and renal disorders.
2.Patients taking medication like glucocorticoids.
3.Pregnant and lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Kalmegh Vati's antihypertensive effects compared to Amlodipine's calcium channel blockade?
How does Kalmegh Vati compare to Amlodipine in managing stage 1 essential hypertension through clinical endpoints like SBP/DBP reduction?
Are there specific biomarkers that predict differential response to Kalmegh Vati versus Amlodipine in essential hypertension patients?
What adverse event profiles differentiate Kalmegh Vati from Amlodipine in stage 1 hypertension management?
How do herbal compounds in Kalmegh Vati compare to other antihypertensive drug classes like ACE inhibitors or ARBs in phase III trials?